W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

News

09 August, 2024
Recommendation of the President – Ultomiris (ravulizumab)
read more
09 August, 2024
Recommendation of the President – Omvoh (mirikizumab)
read more
09 August, 2024
Recommendation of the President – Zolgensma (onasemnogene abeparvovec)
read more
09 August, 2024
Recommendation of the President – Ayvakyt (avapritinib)
read more
08 August, 2024
Opinion of the Transparency Council – active substance sulfasalazinum
read more
08 August, 2024
Opinion of the Transparency Council – active substance octreotidum
read more
08 August, 2024
Opinion of the Transparency Council – active substance lanreotidum
read more
08 August, 2024
Position of the Transparency Council – Kuvan (sapropterin)
read more
08 August, 2024
Position of the Transparency Council – Ultomiris (ravulizumab)
read more
08 August, 2024
Position of the Transparency Council – Omvoh (mirikizumab)
read more
08 August, 2024
Position of the Transparency Council – Zolgensma (onasemnogene abeparvovec)
read more
08 August, 2024
Position of the Transparency Council – Ayvakyt (avapritinib)
read more
08 August, 2024
Communication of the meeting of Transparency Council No. 33/2024 on 5 August 2024
read more
08 August, 2024
The Transparency Council meeting 34/2024 on 12 August 2024
read more
02 August, 2024
Communication – TLI effectiveness evaluation report
read more
02 August, 2024
Recommendation of the President – Gyroscopic stereotactic teleradiotherapy (TSZ) using a novel ZAP-X device
read more
02 August, 2024
Recommendation of the President – Daraprim (pyrimethamine)
read more
01 August, 2024
Opinion of the Transparency Council – doxazosinum (4mg)
read more
01 August, 2024
Opinion of the Transparency Council – doxazosinum (1 mg, 2 mg)
read more
01 August, 2024
Opinion of the Transparency Council – valgancyclovir
read more
01 August, 2024
Position of the Transparency Council – Daraprim
read more
01 August, 2024
Opinion of the Transparency Council – tocilizumab
read more
01 August, 2024
Opinion of the Transparency Council – rituximab
read more
01 August, 2024
Communication of the meeting of Transparency Council No. 32/2024 on 29 July 2024
read more

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑